Comparing Prophylactic Administration of Sulbactam/Ampicillin Versus Cefmetazole for Prevention of Perineal Wound Infection Following Abdominoperineal Resection for Rectal Cancer: A Multicenter Randomized Controlled Trial

比较舒巴坦/氨苄西林与头孢美唑预防直肠癌腹会阴联合切除术后会阴伤口感染的疗效:一项多中心随机对照试验

阅读:2

Abstract

AIM: Perineal wound infection (PWI) is a critical complication unique to abdominoperineal resection (APR) that requires preventive interventions. This study compared the efficacy of a 4-day regimen of sulbactam/ampicillin (SBT/ABPC) with that of a 1-day regimen of cefmetazole (CMZ) for preventing PWI after APR. METHODS: Eighty patients who underwent APR for rectal cancer were enrolled in this multicenter, open-label, randomized controlled trial. The primary outcome was the incidence of PWI, and secondary outcomes included the incidence of surgical site infections (SSI), other complications, and length of postoperative hospital stay. Based on an assumed PWI incidence of 46% for CMZ and 14% for SBT/ABPC, a sample size of 40 participants per group was required to achieve a 90% power at a two-sided 10% significance level. RESULTS: Of the 80 randomized patients, 76 were analyzed in the SBT/ABPC (n = 39) and CMZ (n = 37) groups. The incidence of PWI (10.3% vs. 24.3%, respectively; p = 0.096) was significantly lower in the SBT/ABPC group than in the CMZ group, based on a planned two-sided significance level of 10%. SSI, other complications, including antibiotic-related adverse events, and length of postoperative hospital stay, were not significantly different between the two groups. SBT/ABPC demonstrated broader bacterial coverage than CMZ in the PWI treatment. CONCLUSION: The 4-day SBT/ABPC regimen significantly reduced the incidence of PWI after APR compared to the 1-day CMZ regimen. This simple approach to antibiotic selection may be beneficial for preventing PWI.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。